Sterile Compounding Pharmacy - Multi-State Licensed Lab

$11.3M

Revenue

$7.7M

SDE

1.8x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a sterile compounding pharmacy operating a licensed lab that prepares custom sterile medications, the kind of high-margin, regulated specialty product that retail pharmacies cannot make. The business holds multi-state licensure, which is the real asset here. Each state board approval is a hard-won regulatory moat that takes time, capital, and clean inspection history to obtain, and it lets the pharmacy ship across a wide geographic footprint rather than being boxed into a single market.

The financials tell a striking story: roughly $11.3 million in revenue throwing off $7.7 million in EBITDA, a 68 percent margin that is almost unheard of in pharmacy. That margin profile suggests the business is selling differentiated compounded formulations to prescribers or clinics, not competing on commodity retail fill volume. The listing describes it as highly profitable and growing quickly with fully trained staff already in place.

The asking price of $14 million against $7.7 million EBITDA implies a 1.82x multiple, which is conspicuously cheap for an asset throwing off this kind of cash. A 1.8x EBITDA multiple on a healthcare business with regulatory barriers either signals a motivated seller, a hidden risk in the revenue concentration or compliance posture, or numbers that need serious verification. The gap between the headline economics and the cheap multiple is the entire diligence thesis.

Why we like it

The earnings quality is exceptional on paper, with $7.7 million EBITDA on $11.3 million revenue, a 68 percent margin that dwarfs typical retail pharmacy economics. Margins this fat indicate proprietary or hard-to-replicate sterile formulations rather than commodity dispensing. The cash conversion in a clean compounding operation can be excellent because inventory turns fast and there is no real estate drag.
Multi-state licensure is the durable moat. State board approval for sterile compounding requires clean 503A or 503B compliance, facility inspections, and time, so a buyer is acquiring regulatory access that competitors cannot quickly replicate. This footprint is what justifies a strategic premium over a single-state operator.
Compounded medications are genuinely recession-resistant. Patients on custom sterile preparations, including hormone therapy, ophthalmics, injectables, and shortage-driven formulations, do not stop treatment in a downturn, and prescriber demand is driven by clinical need rather than discretionary spend. The drug shortage environment continues to push demand toward compounders.
The 1.82x EBITDA multiple is the standout opportunity if the numbers verify. Healthcare assets with regulatory barriers routinely trade at 4x to 7x EBITDA, so a clean version of this business at 1.8x represents a dramatic mispricing or a forced sale. Either way, the entry math leaves enormous room for return even with conservative assumptions.

How to improve it

Pursue or expand 503B outsourcing facility registration if not already held, which unlocks the ability to compound in bulk for hospitals and clinics without patient-specific prescriptions. This shifts the model from one-off retail fills to recurring institutional contracts and dramatically expands the addressable market within the first year.
Build a direct prescriber and clinic sales motion to deepen the highest-margin specialty lines. A small dedicated outside sales team calling on physician offices and surgery centers can convert the existing formulation catalog into contracted, repeat ordering relationships rather than relying on inbound demand.
Add additional state licenses methodically using the existing compliant infrastructure as the template. Each new state board approval incrementally widens the shipping footprint and revenue base, and the marginal cost of expansion is low once the quality system and SOPs are already in place.
Implement a formal quality management system audit and pursue any missing accreditations such as PCAB. This both de-risks the regulatory profile and becomes a marketing asset that prescribers and institutional buyers screen for when choosing a compounding partner.
Analyze the formulation mix and prune low-margin or compliance-heavy products while doubling down on the highest-demand sterile preparations. Concentrating production on the most profitable SKUs improves throughput and reduces the regulatory surface area that has to be monitored.
Invest in automation and capacity within the cleanroom to handle volume growth without proportional labor increases. Given the 68 percent margin, reinvesting a slice of cash flow into compounding equipment and batch capacity protects the margin profile as revenue scales.
Diversify the customer and prescriber base if revenue is concentrated. Building relationships across more clinics and geographies reduces the single largest risk to a cash-flow business like this and makes the asset more financeable and more valuable on exit.

Diligence notes

The 1.82x EBITDA multiple on a healthcare asset is the single biggest flag and demands explanation. Press hard on why a business throwing off $7.7 million in cash is priced at $14 million, because the reasons usually involve revenue concentration, a pending regulatory issue, the loss of a key prescriber relationship, or numbers that do not survive a quality of earnings review.
Verify every state license is active, in good standing, and transferable to a new owner. Compounding licenses are tied to facility, personnel, and inspection history, so confirm the full inspection record, any past warning letters, FDA Form 483 observations, or board disciplinary actions that could jeopardize continuity.
Examine revenue concentration by prescriber, payer, and product line. If a handful of physicians or a single high-margin formulation drives most of the EBITDA, the durability of that 68 percent margin is far weaker than it appears and changes the valuation entirely.
Distinguish 503A versus 503B status and confirm compliance posture, because the regulatory and quality requirements differ materially and the FDA scrutinizes outsourcing facilities heavily. Confirm USP 797 and 800 compliance for sterile and hazardous compounding, since a deficiency here can shut the operation down.
Validate the EBITDA with a quality of earnings analysis, including how much owner compensation, addbacks, and any non-recurring items are baked into the $7.7 million figure. Confirm the margin is real and sustainable rather than inflated by aggressive pricing on a temporary drug-shortage product that competitors will erode.
Confirm the trained staff, key pharmacists, and pharmacist-in-charge will remain post-close, since licensure and quality systems depend on credentialed personnel. The loss of the pharmacist-in-charge or key compounders could trigger licensing complications and impair the very margins that justify the deal.

Source

Originally listed on DealStream. View original listing →